ELV vs HUM
Elevance Health and Humana, both Healthcare
Elevance Health is the larger company at $84B against $43B. On trailing earnings ELV is the cheaper of the two at a P/E of 18.3 against 46.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year HUM returned +65% against +33% for ELV. The RyuScore puts ELV ahead, 78 against 73 out of 100.
| Figure | ELV | HUM |
|---|---|---|
| Last close | $413 | $431 |
| Market cap | $84B | $43B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.3 | 46.0 |
| Dividend yield | n/a | 0.8% |
| 1-year return | +33% | +65% |
| 5-year return | +20% | +11% |
| RyuScoresector-relative, 1–10 | 78/100 | 73/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Elevance Health
Revenue of $50B in Q2 2026, net income $1.5B. Its largest reported line is Reportable, 89% of the disclosed total.
Humana
Revenue of $40B in Q1 2026, net income $1.2B. Its largest reported line is Center Well, 89% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.